{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:03:59Z","timestamp":1791288239055,"version":"4.3.0"},"reference-count":305,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1053\/j.seminoncol.2004.09.018","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"106-146","source":"Crossref","is-referenced-by-count":58,"special_numbering":"S13","title":["The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer"],"prefix":"10.1053","volume":"31","author":[{"given":"Nicholas J.","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Craig","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail T.","family":"Colbern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto A.","family":"Gabizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.09.018_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.11859","article-title":"Is breast cancer survival improving?","volume":"100","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/bjc.1988.140","article-title":"Does chemotherapy improve survival in advanced breast cancer? A statistical overview","volume":"57","author":"A\u2019Hern","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2000.18.12.2395","article-title":"Palliative effect of chemotherapy","volume":"18","author":"Geels","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib4","first-page":"15","article-title":"Combination chemotherapy in hormone resistant breast cancer","volume":"10","author":"Cooper","year":"1969","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/1097-0142(197909)44:3<793::AID-CNCR2820440302>3.0.CO;2-Y","article-title":"Adjuvant chemotherapy of breast cancer","volume":"44","author":"Cooper","year":"1979","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/bmj.1.5901.218","article-title":"Cyclical combination chemotherapy for advanced breast carcinoma","volume":"1","author":"Canellos","year":"1974","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-84-4-389","article-title":"Combination chemotherapy for advanced breast cancer","volume":"84","author":"Canellos","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF01806026","article-title":"An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer","volume":"5","author":"Segaloff","year":"1985","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF01655185","article-title":"A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer","volume":"9","author":"Wood","year":"1985","journal-title":"World J Surg"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib10","series-title":"Breast Diseases","first-page":"604","article-title":"Chemotherapy for metastatic disease","author":"Henderson","year":"1991"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00000421-198406000-00007","article-title":"A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study","volume":"7","author":"Tormey","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1200\/JCO.2003.09.006","article-title":"Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1993.146","article-title":"Chemotherapy and survival in advanced breast cancer","volume":"67","author":"A\u2019Hern","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer","volume":"18","author":"Paridaens","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib18","series-title":"Manual of Oncologic Therapeutics","first-page":"153","article-title":"Breast cancer","author":"Ravdin","year":"1995"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib19","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.1998.16.11.3493","article-title":"Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients","volume":"16","author":"Shapiro","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib20","series-title":"Cancer","first-page":"1557","article-title":"Malignant tumors of the breast","author":"Harris","year":"1997"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","article-title":"Epirubicin","volume":"4","author":"Cersosimo","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib22","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","article-title":"Epirubicin cardiotoxicity","volume":"16","author":"Ryberg","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib23","first-page":"140","article-title":"Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer","volume":"2","author":"Findlay","year":"1998","journal-title":"Cancer Prev Control"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib24","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","article-title":"Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer","volume":"16","author":"Levine","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.09.018_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","article-title":"Cardiac safety of liposomal anthracyclines","volume":"31","author":"Ewer","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM198809223191203","article-title":"Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer","volume":"319","author":"Speyer","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.1992.10.1.117","article-title":"ICRF-187 permits longer treatment with doxorubicin in women with breast cancer","volume":"10","author":"Speyer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib29","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/1097-0142(19810415)47:8<1959::AID-CNCR2820470808>3.0.CO;2-X","article-title":"Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy","volume":"47","author":"Liesmann","year":"1981","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib30","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib31","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"Mitoxantrone","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<740::AID-CNCR11>3.0.CO;2-#","article-title":"Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma","volume":"79","author":"Hainsworth","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib35","series-title":"Cancer Medicine","first-page":"1005","article-title":"Anticancer drugs from plants","author":"Beck","year":"1993"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib37","series-title":"Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer","author":"Jones","year":"2003"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib38","first-page":"382","article-title":"Pegfilgrastim to reduce the incidence of febrile neutropenia in patients with breast cancer receiving docetaxel","volume":"12","author":"Schwartzberg","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib39","first-page":"S17-87","article-title":"Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer","volume":"24","author":"Akerley","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib40","first-page":"174a","article-title":"Phase II study of weekly paclitaxel in recurrent breast cancer after high-dose chemotherapy (HDC)","volume":"17","author":"Sola","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib41","first-page":"127a","article-title":"Weekly moderate-dose paclitaxel in advanced breast cancer","volume":"17","author":"Asbury","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib42","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1015230212550","article-title":"Weekly paclitaxel in women age 65 and above with metastatic breast cancer","volume":"73","author":"Perez","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib44","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced breast cancer","volume":"19","author":"Hainsworth","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib45","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","article-title":"Docetaxel administered on a weekly basis for metastatic breast cancer","volume":"18","author":"Burstein","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00000421-200108000-00021","article-title":"A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors","volume":"24","author":"Kouroussis","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s002800000184","article-title":"A dose escalation study of weekly docetaxel in patients with advanced solid tumors","volume":"46","author":"Kouroussis","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib48","first-page":"32","article-title":"Is there a place for \u201cdose-dense\u201d weekly schedules of the taxoids?","volume":"25","author":"Loffler","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib49","first-page":"65","article-title":"CALGB 9840","volume":"23","author":"Seidman","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib50","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.1999.17.11.3403","article-title":"Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib51","first-page":"110a","article-title":"Final results","volume":"17","author":"Holmes","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib52","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1996.14.6.1858","article-title":"Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer","volume":"14","author":"Nabholtz","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib53","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0889-8588(05)70063-0","article-title":"The role of chemotherapy for metastatic breast cancer","volume":"13","author":"Miller","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib55","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1023\/A:1011655503511","article-title":"Cardiac function following combination therapy with paclitaxel and doxorubicin","volume":"12","author":"Gianni","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","article-title":"Combined doxorubicin and paclitaxel in advanced breast cancer","volume":"7","author":"Gehl","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib57","first-page":"160a","article-title":"Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCl liposome injection (Doxil) plus paclitaxel (DT) in metastatic breast cancer","volume":"17","author":"Moore","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2001.26434","article-title":"Doxorubicin and taxane combination regimens for metastatic breast cancer","volume":"28","author":"Valero","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib59","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","article-title":"Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer","volume":"19","author":"Jassem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib60","first-page":"36a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib61","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib62","first-page":"73a","article-title":"Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin\/paclitaxel (ET) vs epirubicin\/cyclophosphamide (EC). A study of the AGO breast cancer group","volume":"19","author":"Luck","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib63","first-page":"23a","article-title":"HER-2\/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer","volume":"20","author":"Konecny","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib64","first-page":"765","article-title":"Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma","volume":"23","author":"Gebbia","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib65","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib66","first-page":"4","article-title":"Paclitaxel (T) following doxorubicin\/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer","volume":"22","author":"Mamounas","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib67","series-title":"TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001","author":"Martin","year":"2003"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib68","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib69","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1200\/JCO.2000.18.12.2385","article-title":"Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic\/recurrent breast cancer","volume":"18","author":"Norris","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib70","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1091::AID-CNCR12>3.0.CO;2-A","article-title":"A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma","volume":"85","author":"Blajman","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib71","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0959-8049(01)00093-4","article-title":"Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC\/FEC in front-line therapy of metastatic breast cancer","volume":"37","author":"Namer","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib72","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1200\/JCO.2004.11.503","article-title":"Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer","volume":"22","author":"Ejlertsen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib73","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib74","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.1999.17.10.3082","article-title":"Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer","volume":"17","author":"Leung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.4-1-17","article-title":"Monotherapy of metastatic breast cancer","volume":"4","author":"Vogel","year":"1999","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib76","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib77","first-page":"104a","article-title":"Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients","volume":"19","author":"Michaud","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib78","first-page":"104a","article-title":"A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)","volume":"19","author":"O\u2019Shaughnessy","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib79","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O\u2019Shaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib80","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1053\/j.seminoncol.2004.09.018_bib81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1634\/theoncologist.2002-0013","article-title":"Combination versus sequential single-agent therapy in metastatic breast cancer","volume":"7","author":"Miles","year":"2002","journal-title":"Oncologist"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.09.018_bib82","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3816\/CBC.2002.s.002","article-title":"Overview","volume":"3","author":"Tripathy","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib83","first-page":"11","article-title":"Gemcitabine as single-agent therapy in the management of advanced breast cancer","volume":"15","author":"Seidman","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000048240","article-title":"Gemcitabine as first-line therapy in patients with metastatic breast cancer","volume":"62","author":"Blackstein","year":"2002","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001813-199902000-00003","article-title":"Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer","volume":"10","author":"Possinger","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib86","first-page":"7","article-title":"Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC)","volume":"22","author":"O\u2019Shaughnessy","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2004.09.018_bib87","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3816\/CBC.2004.s.003","article-title":"Gemcitabine and taxanes as a new standard of care in breast cancer","volume":"4","author":"Yardley","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3816\/CBC.2001.n.022","article-title":"Platinum compounds in the treatment of advanced breast cancer","volume":"2","author":"Martin","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00257133","article-title":"CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study","volume":"13","author":"Kolaric","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/030089168907500210","article-title":"Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer","volume":"75","author":"Kolaric","year":"1989","journal-title":"Tumori"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib91","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.1984.2.11.1260","article-title":"A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer","volume":"2","author":"Creagan","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib92","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/annonc\/mdh175","article-title":"A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer","volume":"15","author":"Smith","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib93","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib94","series-title":"A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel+carboplatin for first-line metastatic breast cancer","author":"Robert","year":"2003"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib95","first-page":"20","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer","volume":"23","author":"Robert","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0093-7754(01)90289-1","article-title":"HER2 overexpression and cancer targeting","volume":"28","author":"Wang","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib97","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4065\/77.2.148","article-title":"HER2 testing in patients with breast cancer","volume":"77","author":"Perez","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib98","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02967477","article-title":"Biological and clinical significance of HER2 overexpression in breast cancer","volume":"8","author":"Kurebayashi","year":"2001","journal-title":"Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib99","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2004.04.158","article-title":"HER-2 testing and trastuzumab therapy for metastatic breast cancer","volume":"22","author":"Elkin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","article-title":"Mechanism of action of trastuzumab and scientific update","volume":"28","author":"Baselga","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib101","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib102","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib103","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib104","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib105","first-page":"84","article-title":"Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin)","volume":"26","author":"Osoba","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib106","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/sj.onc.1202132","article-title":"Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs","volume":"17","author":"Pietras","year":"1998","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib107","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3816\/CBC.2004.n.005","article-title":"Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer","volume":"4","author":"Raff","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib109","first-page":"131a","article-title":"A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2","volume":"19","author":"Kuzur","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnci\/djh133","article-title":"Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib111","first-page":"21","article-title":"Trastuzumab and chemotherapeutics","volume":"27","author":"Pegram","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib112","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer","volume":"21","author":"Burstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib113","first-page":"67","article-title":"Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer","volume":"23","author":"Bayo","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib114","first-page":"36","article-title":"Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC)","volume":"23","author":"Porta","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib115","first-page":"59","article-title":"Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer","volume":"23","author":"Bernardo","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib116","first-page":"83","article-title":"Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC)","volume":"23","author":"De Wit","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib117","first-page":"235","article-title":"Trastuzumab (T) plus Vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer","volume":"23","author":"Glogowska","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib118","first-page":"66","article-title":"Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC)","volume":"23","author":"Morabito","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib119","first-page":"37","article-title":"First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC)","volume":"23","author":"Yardley","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib120","first-page":"24","article-title":"erbB-2 positive specimens from previously-untreated breast cancer patients have in vitro drug resistance profiles which resemble profiles of specimens obtained from patients who have previously failed combination chemotherapy","volume":"9","author":"Lippman","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib121","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","article-title":"HER-2\/neu in node-negative breast cancer","volume":"10","author":"Allred","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib122","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","article-title":"Prognostic importance of c-erbB-2 expression in breast cancer","volume":"10","author":"Gusterson","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib123","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2001.19.2.329","article-title":"Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables","volume":"19","author":"Menard","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib124","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","article-title":"c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer","volume":"330","author":"Muss","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib125","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/90.18.1361","article-title":"erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer","volume":"90","author":"Paik","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib126","first-page":"374a","article-title":"Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone","volume":"16","author":"Ravdin","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib127","first-page":"71a","article-title":"HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer","volume":"18","author":"Vera","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1023077507295","article-title":"HER-2\/neu and topoisomerase IIalpha in breast cancer","volume":"78","author":"Jarvinen","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib129","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.1987.5.12.1928","article-title":"The effect on survival of initial chemotherapy in advanced breast cancer","volume":"5","author":"Ahmann","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib130","first-page":"1","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women","volume":"339","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib131","first-page":"1","article-title":"Adjuvant breast cancer therapy","volume":"26","author":"Norton","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib132","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.273.7.542","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib133","first-page":"36a","article-title":"Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (intergroup 0137)","volume":"21","author":"Haskell","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib134","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib135","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib136","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/annonc\/mdf306","article-title":"Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial","volume":"13","author":"Heidemann","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib137","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib138","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib139","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/JCO.1988.6.9.1377","article-title":"A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer","volume":"6","author":"Tannock","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.1987.5.3.354","article-title":"Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units","volume":"5","author":"Hortobagyi","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib141","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1997.15.5.1858","article-title":"Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib142","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.1999.17.11.3374","article-title":"Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer","volume":"17","author":"Fisher","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib143","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1996.14.4.1146","article-title":"Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer","volume":"14","author":"Bastholt","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib144","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1008295427877","article-title":"Doubling epirubicin dose intensity (100 mg\/m2 versus 50 mg\/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer","volume":"8","author":"Brufman","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib145","first-page":"769","article-title":"Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen","volume":"16","author":"Riccardi","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jnci\/92.3.225","article-title":"Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma","volume":"92","author":"Hortobagyi","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib147","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","article-title":"Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement","volume":"352","author":"Rodenhuis","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib148","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0140-6736(00)02841-5","article-title":"Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study","volume":"356","author":"Bergh","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib149","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1200\/JCO.2003.03.034","article-title":"Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide","volume":"21","author":"Papaldo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib150","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM198712103172402","article-title":"Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies","volume":"317","author":"Coates","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib151","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","article-title":"Interrupted versus continuous chemotherapy in patients with metastatic breast cancer","volume":"325","author":"Muss","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib152","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/oxfordjournals.annonc.a057671","article-title":"A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)","volume":"1","author":"Cocconi","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib153","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.1998.16.5.1669","article-title":"Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment","volume":"16","author":"Falkson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib154","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0959-8049(05)80145-5","article-title":"Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months","volume":"29A","author":"Ejlertsen","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib155","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2000.18.17.3115","article-title":"Epirubicin-based chemotherapy in metastatic breast cancer patients","volume":"18","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib156","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/0277-5379(91)90259-G","article-title":"\u201cClassical\u201d CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)","volume":"27","author":"Engelsman","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib157","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197602192940801","article-title":"Combination chemotherapy as an adjuvant treatment in operable breast cancer","volume":"294","author":"Bonadonna","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib158","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1023\/A:1008236502420","article-title":"Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen","volume":"9","author":"Goldhirsch","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib159","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1994.259","article-title":"Continuous 5-fluorouracil in the treatment of breast cancer","volume":"70","author":"Cameron","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1006062018355","article-title":"Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin","volume":"50","author":"Nieto","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib161","first-page":"3553","article-title":"Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion","volume":"19","author":"Gebbia","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib162","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/oxfordjournals.annonc.a010759","article-title":"Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer","volume":"7","author":"Regazzoni","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib163","first-page":"35","article-title":"Long term continuous 5-fluorouracil infusion in the treatment of far advanced metastatic breast carcinoma","volume":"8","author":"Hatfield","year":"1989","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib164","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000421-198910000-00019","article-title":"Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer","volume":"12","author":"Chang","year":"1989","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF01810577","article-title":"Continuous 5-fluorouracil infusion in refractory carcinoma of the breast","volume":"10","author":"Hansen","year":"1987","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib166","first-page":"279","article-title":"(Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide)","volume":"73","author":"Palangie","year":"1986","journal-title":"Bull Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib167","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib168","first-page":"231","article-title":"Adriamycin (NSC-123127) studies at the Instituto Nazionale Tumori, Milan","volume":"6","author":"Bonadonna","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib169","first-page":"813","article-title":"Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity","volume":"60","author":"Weiss","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib170","first-page":"877","article-title":"Weekly dose adriamycin as first line chemotherapy in advanced breast cancer","volume":"11","author":"Jonsson","year":"1991","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib171","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/02841868809093543","article-title":"Weekly low-dose doxorubicin with or without high-dose medroxyprogesterone acetate as secondary treatment in metastatic breast cancer-a randomized trial","volume":"27","author":"Elomaa","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib172","first-page":"47","article-title":"Adriamycin given as a weekly schedule without a loading course","volume":"64","author":"Chlebowski","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib173","first-page":"193","article-title":"A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer","volume":"5","author":"Mattsson","year":"1982","journal-title":"Clin Ther"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib174","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000421-199102000-00009","article-title":"Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial","volume":"14","author":"Gasparini","year":"1991","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib175","first-page":"815","article-title":"Weekly low-dose doxorubicin in advanced breast cancer","volume":"70","author":"Specenier","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib176","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0277-5379(86)90075-1","article-title":"Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial","volume":"22","author":"Gundersen","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib177","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-99-6-745","article-title":"Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy","volume":"99","author":"Torti","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib178","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib179","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00000421-198902000-00014","article-title":"A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer","volume":"12","author":"Hortobagyi","year":"1989","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib180","first-page":"133","article-title":"Clinical evaluation of long-term, continuous-infusion doxorubicin","volume":"67","author":"Garnick","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib181","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.1983.1.1.24","article-title":"Constant infusion schedule for adriamycin","volume":"1","author":"Lokich","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib182","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a057719","article-title":"Phase I-II constant infusion of adriamycin (doxorubicin) by ambulatory pump delivery system in heavily pretreated (including adriamycin) breast cancer patients","volume":"1","author":"Jasmin","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib183","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib184","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2004.09.018_bib185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1081\/CNV-120014883","article-title":"Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer","volume":"20","author":"Perez","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib186","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib187","first-page":"96a","article-title":"The use of neoadjuvant Doxil in the treatment of stage III breast cancer","volume":"18","author":"Hurley","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.09.018_bib188","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin","volume":"31","author":"Vail","year":"2004","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.09.018_bib189","first-page":"S132","article-title":"An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx in metastatic breast cancer patients","volume":"76","author":"Coleman","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib190","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib191","series-title":"Xeloda (capecitabine) prescribing information","year":"2003"},{"issue":"suppl A","key":"10.1053\/j.seminoncol.2004.09.018_bib192","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0305-7372(93)90060-5","article-title":"Evaluation of effectiveness","volume":"19","author":"Gelber","year":"1993","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"10.1053\/j.seminoncol.2004.09.018_bib193","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib194","first-page":"137a","article-title":"Phase II study of DOXIL (pegylated liposomal doxorubicin) in doxorubicin-resistant, metastatic breast cancer","volume":"18","author":"Smith","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00280-001-0405-3","article-title":"Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer","volume":"49","author":"Rivera","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib196","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib197","first-page":"146a","article-title":"Doxil and oral cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC)","volume":"17","author":"Holder","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib198","first-page":"115a","article-title":"Doxil and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC)","volume":"18","author":"Silverman","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib199","article-title":"Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer","author":"Overmoyer","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib200","first-page":"70a","article-title":"Phase II study with the combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC)","volume":"21","author":"Srimuninnimit","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib201","first-page":"245a","article-title":"Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel","volume":"17","author":"Israel","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib202","first-page":"246a","article-title":"Phase II trial to evaluate the safety and tolerability of Caelyx (Doxil) in combination with paclitaxel in the treatment of metastatic cancer","volume":"17","author":"Langley","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib203","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000059568","article-title":"Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors","volume":"62","author":"Mavroudis","year":"2002","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib204","first-page":"52","article-title":"A phase I study of paclitaxel in combination with pegylated liposomal doxorubicin (PLD) as second-line chemotherapy in metastatic breast cancer (MBC)","volume":"22","author":"Lortholary","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib205","first-page":"116a","article-title":"Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer","volume":"19","author":"Jones","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib206","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00001813-200010000-00002","article-title":"Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer","volume":"11","author":"Schwonzen","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib207","first-page":"67b","article-title":"Doxil\/Caelyx (D) plus paclitaxel (T) in patients with metastatic breast cancer (MBCA)","volume":"20","author":"Woll","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib208","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/annonc\/mdf284","article-title":"Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer","volume":"13","author":"Gogas","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib209","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/annonc\/mdh218","article-title":"Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer","volume":"15","author":"Alexopoulos","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib210","first-page":"1817","article-title":"Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients","volume":"10","author":"Rigatos","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib211","first-page":"52","article-title":"Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients","volume":"23","author":"Fulfaro","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib212","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.breast.2004.01.006","article-title":"First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer","volume":"13","author":"Vorobiof","year":"2004","journal-title":"Breast"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib213","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib214","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2001.19.12.3117","article-title":"Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer","volume":"19","author":"Sparano","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib215","first-page":"167a","article-title":"A phase I study of Taxotere and Doxil in patients with advanced malignancies","volume":"18","author":"Wasserheit","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib216","first-page":"825a","article-title":"Doxil and docetaxel (Taxotere)","volume":"19","author":"Chodkiewicz","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib217","first-page":"213a","article-title":"Phase I study of Doxil in combination with escalating doses of Taxotere in the treatment of patients with advanced malignancies","volume":"18","author":"Hirsch","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib218","first-page":"230a","article-title":"A phase I study of Taxotere (T) and Doxil (D) in refractory cancer","volume":"19","author":"Tauer","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib219","first-page":"213a","article-title":"Phase I studies of weekly docetaxel with Doxil or weekly doxorubicin","volume":"19","author":"Lopez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib220","first-page":"85b","article-title":"Phase I weekly docetaxel with doxorubicin or Doxil","volume":"20","author":"Sikov","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib221","first-page":"209a","article-title":"A phase I trial of liposomal doxorubicin (Doxil) given on day one followed by docetaxel (Taxotere) given on day five in patients with advanced solid tumors","volume":"18","author":"Drinkard","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib222","first-page":"80","article-title":"Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC)","volume":"23","author":"Guastalla","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib223","series-title":"Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC)","author":"Wolff","year":"2004"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib224","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00280-003-0750-5","article-title":"Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel","volume":"53","author":"Briasoulis","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib225","first-page":"254a","article-title":"Combined antitumor therapy with Doxil and Navelbine in HT29 colon xenografts","volume":"17","author":"Vaage","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000065716","article-title":"Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation","volume":"63","author":"Gebbia","year":"2002","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib227","first-page":"38b","article-title":"Phase II study of pegilated liposomal doxorubicin plus vinorelbine in metastatatic breast cancer patients with prior anthracycline treatment","volume":"21","author":"Martin","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib228","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1023\/A:1021300719965","article-title":"Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer","volume":"77","author":"Rimassa","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib229","first-page":"246a","article-title":"Phase I trial of DOXIL plus vinorelbine (VNB) in patients (pts) with advanced malignancies","volume":"17","author":"Laufman","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib230","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1023\/A:1008323200102","article-title":"Phase I study of Doxil and vinorelbine in metastatic breast cancer","volume":"10","author":"Burstein","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib231","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2003.03.111","article-title":"Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer","volume":"21","author":"Rivera","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib232","first-page":"79","article-title":"Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients","volume":"23","author":"Fabi","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib233","first-page":"50","article-title":"Multicenter phase II trial of gemcitabine plus liposomal doxorubicin in chemotherapeutically pretreated patients with advanced breast cancer (ABC)","volume":"23","author":"Haider","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib234","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1200\/JCO.2001.19.6.1716","article-title":"Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer","volume":"19","author":"Rivera","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib235","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib236","unstructured":"Colbern G, Hiller A, Musterer R, et al: Antitumor activity of Herceptin in combination with DOXIL or nonencapsulated doxorubicin in a HER2 positive breast cancer model. San Antonio Breast Cancer Symposium, 1998, pp 320 (abstr 519)"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib237","first-page":"34","article-title":"A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)","volume":"23","author":"Chia","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib238","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/annonc\/mdf280","article-title":"Heating the patient","volume":"13","author":"van der Zee","year":"2002","journal-title":"Ann Oncol"},{"issue":"suppl 13","key":"10.1053\/j.seminoncol.2004.09.018_bib239","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib240","first-page":"90a","article-title":"Phase I\/II study of sequential hyperthermia + Doxil for the treatment of breast cancer metastatic to the chest wall","volume":"19","author":"Park","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib241","first-page":"47a","article-title":"Hyperthermia (HT) + Doxil significantly enhances drug delivery and efficacy in metastatic breast cancer of the chest wall (CW)","volume":"20","author":"Park","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib242","first-page":"501a","article-title":"Fever range hyperthermia and pegylated liposomal doxorubicin in the treatment of advanced breast cancer","volume":"17","author":"Bull","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib243","first-page":"374","article-title":"Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer","volume":"8","author":"Kouloulias","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib244","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib245","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.1999.17.5.1435","article-title":"Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer","volume":"17","author":"Shapiro","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib246","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1999.17.5.1425","article-title":"Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer","volume":"17","author":"Valero","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib247","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib248","first-page":"459a","article-title":"Phase III study of TLC D-99 (liposome encapsulated doxorubicin) plus cyclophosphamide vs. epirubicin (EPI) plus cyclophosphamide (CPA) in patients with metastatic breast carcinoma (MBC)","volume":"18","author":"Erdkamp","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib249","first-page":"55a","article-title":"TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC)","volume":"21","author":"Theodoulou","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib250","first-page":"61a","article-title":"Cardiac safety and activity of a phase I study of 3-weekly myocet in combination with weekly herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer (LA\/MBC)","volume":"21","author":"Trigo","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.09.018_bib251","first-page":"583","article-title":"Liposomal doxorubicin (MYOCET) in combination with HERCEPTIN and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer (LA\/MBC)","volume":"82","author":"Trigo","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib252","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","article-title":"Taxanes for breast cancer","volume":"1","author":"Sparano","year":"2000","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib253","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002512-199915050-00006","article-title":"Epirubicin","volume":"15","author":"Ormrod","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib254","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/02841868909092326","article-title":"Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems","volume":"28","author":"Ebbs","year":"1989","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib255","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1006394801389","article-title":"Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients","volume":"59","author":"Michelotti","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib256","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3816\/CBC.2001.n.016","article-title":"A review of vinorelbine in the treatment of breast cancer","volume":"2","author":"Domenech","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib257","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CBC.2001.n.003","article-title":"Capecitabine in breast cancer","volume":"1","author":"Smorenburg","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib258","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib259","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"issue":"suppl 6","key":"10.1053\/j.seminoncol.2004.09.018_bib260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_6-20","article-title":"Single-agent capecitabine","volume":"7","author":"Seidman","year":"2002","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib261","first-page":"877","article-title":"Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer","volume":"58","author":"Ahmann","year":"1974","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib262","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/0277-5379(86)90149-5","article-title":"New anthracycline analogs in advanced breast cancer","volume":"22","author":"Bonfante","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib263","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.1989.234","article-title":"The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer","volume":"60","author":"Bronchud","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib264","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1002\/1097-0142(197706)39:6<2916::AID-CNCR2820390678>3.0.CO;2-Z","article-title":"Chemotherapy of disseminated breast cancer. Current status and prospects","volume":"39","author":"Carbone","year":"1977","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib265","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/bjc.1987.226","article-title":"A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma","volume":"56","author":"Carmo-Pereira","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib266","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/0959-8049(94)00213-O","article-title":"Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study","volume":"30A","author":"Gundersen","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib267","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1097-0142(197607)38:1<13::AID-CNCR2820380104>3.0.CO;2-5","article-title":"Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study","volume":"38","author":"Hoogstraten","year":"1976","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib268","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.1987.5.2.172","article-title":"A phase I-II study of intensive-dose adriamycin for advanced breast cancer","volume":"5","author":"Jones","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib269","first-page":"253","article-title":"Adriamycin (NSC-123127) studies in adult patients","volume":"6","author":"Krakoff","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0936-6555(05)80851-9","article-title":"A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma","volume":"5","author":"Lawton","year":"1993","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib271","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1","article-title":"A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer","volume":"64","author":"Lopez","year":"1989","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib272","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.1991.9.12.2148","article-title":"A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer","volume":"9","author":"Perez","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib273","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0277-5379(83)90085-8","article-title":"Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer","volume":"19","author":"Steiner","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib274","first-page":"1594","article-title":"Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer","volume":"66","author":"Taylor","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib275","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0959-8049(92)90447-A","article-title":"Doxorubicin in advanced breast cancer","volume":"28A","author":"Richards","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib276","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/1097-0142(197806)41:6<2078::AID-CNCR2820410602>3.0.CO;2-Q","article-title":"Adriamycin in combination for the treatment of breast cancer","volume":"41","author":"Tranum","year":"1978","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib277","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/1097-0142(19820301)49:5<835::AID-CNCR2820490502>3.0.CO;2-Z","article-title":"Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study","volume":"49","author":"Tranum","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib278","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3109\/02841868809094360","article-title":"Weekly low-dose doxorubicin as second line therapy in advanced breast cancer","volume":"27","author":"Elomaa","year":"1988","journal-title":"Acta Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib279","first-page":"1181","article-title":"Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer","volume":"70","author":"Andersson","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M","article-title":"Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule","volume":"33","author":"Benjamin","year":"1974","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib281","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/1097-0142(19800801)46:3<433::AID-CNCR2820460302>3.0.CO;2-6","article-title":"An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients","volume":"46","author":"Creech","year":"1980","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib282","first-page":"88","article-title":"A randomized trial of adriamycin versus mitomycin at low doses in CMF-refractory metastatic breast cancer patients","volume":"1","author":"Creech","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib283","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/83.15.1077","article-title":"Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer","volume":"83","author":"Cowan","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib284","first-page":"63","article-title":"Single-agent Adriamycin","volume":"15","author":"Rosner","year":"1976","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib285","first-page":"1701","article-title":"Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer","volume":"63","author":"Ingle","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib286","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000421-198508000-00001","article-title":"Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure","volume":"8","author":"Ingle","year":"1985","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib287","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00000421-198912000-00003","article-title":"Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer","volume":"12","author":"Ingle","year":"1989","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib288","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1985.3.6.818","article-title":"A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer","volume":"3","author":"Jain","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib289","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/1097-0142(19820501)49:9<1762::AID-CNCR2820490905>3.0.CO;2-Q","article-title":"Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer","volume":"49","author":"Legha","year":"1982","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib290","first-page":"111","article-title":"Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer","volume":"64","author":"Manni","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib291","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.1986.4.5.672","article-title":"A comparison of mitoxantrone and doxorubicin in breast cancer","volume":"4","author":"Neidhart","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib292","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0","article-title":"Dose response evaluation of adriamycin in human neoplasia","volume":"39","author":"O\u2019Bryan","year":"1977","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib293","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0277-5379(86)90050-7","article-title":"Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group","volume":"22","author":"Van Oosterom","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib294","first-page":"449","article-title":"Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone","volume":"62","author":"Frederiksen","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib295","first-page":"27","article-title":"Phase II trial of weekly low dose doxorubicin in advanced breast cancer","volume":"7","author":"Frenay","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib296","first-page":"519","article-title":"Proceedings","volume":"33","author":"Gottlieb","year":"1974","journal-title":"A Southwest Cancer Chemotherapy study Group study. Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib297","first-page":"40","article-title":"Reutilization of doxorubicin in patients with progressive metastatic breast cancer","volume":"7","author":"Ro","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib298","first-page":"48","article-title":"Adriamycin versus epirubicin: low-dose weekly schedule in metastatic breast cancer. Preliminary results of tumor response and of quality-of-life measurements","volume":"9","author":"Castiglione","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib299","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF01806014","article-title":"Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment","volume":"6","author":"Scheithauer","year":"1985","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib300","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/mpo.2950160505","article-title":"VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial","volume":"16","author":"Vaughn","year":"1988","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib301","first-page":"247","article-title":"An overview of studies with adriamycin (NSC-123127) in the United States","volume":"6","author":"Blum","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib302","series-title":"Herceptin (trastuzumab) prescribing information","year":"2003"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib303","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.1998.16.12.3720","article-title":"Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer","volume":"16","author":"Joensuu","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib304","first-page":"5","article-title":"Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC)","volume":"23","author":"Albain","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.018_bib305","first-page":"54b","article-title":"Phase I-II study of liposomial doxorubicin and docetaxel as first-line treatment in patients with advanced breast cancer","volume":"21","author":"Gasparini","year":"2002","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404004154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404004154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:02:48Z","timestamp":1586538168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404004154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":305,"alternative-id":["S0093775404004154"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.09.018","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}